Directory · CN
Pharmaceutical Manufacturing in China
A register of firms and the professionals working at them in the Pharmaceutical Manufacturing sector based in China. Browse the public index, then filter or export on Kipplo.
Companies
1.5K on file
Viatris
Viatris Inc.(NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S, with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: Connect with Viatris Instagram: X: Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.
10001+ staff
Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co, Ltd.("Fosun Pharma"; SSE: 600196, HKEX: 02196) is a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co, Ltd, Fosun Pharma further extends its capabilities in pharmaceutical commerce. Over the past 30 years since its establishment, Fosun Pharma has maintained deep roots in China while strategically expanding its global presence. The company has been actively implementing its “4IN” strategy -Innovation, Internationalization, Intelligentization, and Integration, with core business operations now spanning major overseas markets including the United States, Europe, Africa, India, and Southeast Asia. At present, Fosun Pharma has established an open and globally integrated pharmaceutical R&D ecosystem, focusing on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery. This multidimensional approach accelerates the translation of innovative therapies into clinical practice, systematically addressing critical unmet medical needs worldwide. Looking ahead, Fosun Pharma remains anchored in its core values of “Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership”. By advancing its global innovation engine and operational excellence, the company strives to be a global leader to integrate pharmaceutical and healthcare innovations, creating better health for families worldwide.
10001+ staff
Qilu Pharmaceuticals
Established in 1958 and headquartered in Jinan, China, Qilu Pharmaceuticals is a large and comprehensive pharmaceutical company specializing in R&D, manufacture, sales and international trade of both APIs and drug products.
10001+ staff
China Pharmaceutical University
China Pharmaceutical University (CPU), situated in the historical and cultural city of Nanjing, is one of the “211 project” key universities affiliated to the Ministry of Education of China. Over the past 80 years since its establishment, the University has been sticking to the motto of “Dedicated to Academic Excellence and Devoted to Public Health” and adopts the developmental strategy of “Beyond Pharmacy, Around Pharmacy and For Pharmacy” (1). Discipline and programs China Pharmaceutical University (CPU), offers 24 bachelor’s degree programs, 5 associate programs, 37 Master degree programs, 24 Doctoral degree programs, and 2 Post-doctoral mobile stations. In 2008s national discipline evaluation by the Chinese Ministry of Education.(2). China Pharmaceutical University Achievement Since 2006, China Pharmaceutical University researchers have applied for 750 patents and attained 409 of them. 11 new drugs have been approved for clinical research and 9 new drugs have been nationally certified. 5375 research papers have been published in core journals, in which 3100 can be retrieved from SCI and EI. China Pharmaceutical University researchers have won 1 First Prize and 3 Second Prizes of National Science and Technology Progress Award, 27 Science and Technology Progress Award at province- or ministry-level. In the last decade, 8457 cooperation agreements have been signed between China Pharmaceutical University and pharmaceutical enterprises. In 2010’s ESI statistics, pharmacology and toxicology, chemistry, as well as clinical pharmacy programs ranked the world’s top 1%. Among China’s national medical universities, China Pharmaceutical University is the only one that has won First Prize of National Teaching Achievements for consecutively three times. The graduate employment rate has always ranked top among MOE-affiliated universities and local colleges in Jiangsu Province.
10001+ staff
Wuxi Chemistry
WuXi Chemistry, a business division of WuXi AppTec, provides contract services for new drug development from discovery to commercial. Our unique CRDMO model offers an integrated solution combining traditional CRO (contract research organization), CDMO (contract development and manufacturing organization) and CMO (contract manufacturing organization) services under one roof. As a world leading chemistry service organization, WuXi Chemistry have over employees from our 16 research, development or manufacturing sites worldwide, serving over clients from top pharma to virtual biotech companies. Our services cover all categories for all synthetic molecular modalities, meeting any material requirement at any scale. Visit STA, CRDMO for small molecule drugs: https://sta.wuxiapptec.com/ Visit WuXi TIDES, CRDMO for oligonucleotide, peptide, and conjugates: https://tides.wuxiapptec.com/
10001+ staff
Wuxi Discovery Services
Enabling Unbounded Possibilities WuXi Discovery Services supports clients in the discovery and development of future therapeutics. Through comprehensive discovery and technology platforms, peer-recognized scientific leadership and expertise in oncology, immunology, infectious disease, neurosciences, fibrosis, cardiovascular and metabolic disease, WuXi AppTec works collaboratively to rapidly advance programs from target through to preclinical selection and beyond. This integration of capabilities allows a collaborative environment, enabling enhanced efficiency and productivity. We strive to continually develop and enhance our scientific capabilities and technology, and to provide outstanding services to our existing partners and to the broader discovery community. Biology Services: http://wuxibiology.com/ Chemistry Services: https://rcs.wuxiapptec.com/
10001+ staff
Shanghai Pharmaceuticals Holding Co., Ltd
Shanghai Pharmaceuticals Holding Co. Ltd.(“SPH”) is a vertically-integrated and diversified pharmaceutical group. The company has dual listings on the stock exchanges in Shanghai (601607) and Hong Kong (02067) respectively. The company provides leading healthcare services in: Research & Development, Manufacturing, Distribution and Retail. In 2019, SPH reported revenues of US$26.5bn, making the company one of the country’s major forces in the industry. SPH is one of the few listed pharmaceutical companies with a leading position in both manufacturing and distribution in China. It is included in the constituent stocks of the SSE 180, CSI 300 indices and MSCI.
10001+ staff
Wuxi Apptec China
Established in December WuXi AppTec (NYSE: WX) is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with operations in China and the United States. WuXi AppTec has successfully established a fully integrated services and technology platform during the past decade. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services. WuXi AppTec has developed from four founders and a single laboratory in December to employees and 5 million square feet of laboratory and manufacturing space, including facilities under construction. The company is actively improving its capabilities and capacity through new expansions in its global business. Capitalizing on the great advantage of conducting R&D services both in China and in the U.S, WuXi AppTec is building an alternative R&D engine to serve the global life-science industry. API 12 4 46
10001+ staff
Dia
DIA is the leading global life science membership association driving collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C, and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.
51 to 200 staff
Shenzhen Neptunus Group Co., Ltd
A giant group in China with subsidiaries focusing on pharmaceutical and healthfood R&D, Manufacturing, Wholesale and Retail, Export & Import. 3 Public companies listed in Shenzhen Stock Exchange, HKEX and NYSE. Worldwide partners needed in Oncology Medicine, Health Food and Herbal Medicine Import & Export, Technical Collaboration, and Contract Manufacturing.
10001+ staff
Gan & Lee Pharmaceuticals
Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions. Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.
1001 to 5000 staff
Zhejiang Huahai Pharmaceutical Co., Ltd
Zhejiang Huahai Pharmaceutical Co,Ltd. is a multinational enterprise, committed to providing high-quality medical and health products to patients around the world. The company is mainly engaged in the development, production and sales of APIs (Active Pharmaceutical ingredients), intermediates and medical preparations that cover fields such as cardiovascular, psychiatric, anti-virus and anti-histamine. Currently, the company has owned more than 30 subsidiaries and has built long-term cooperative relationships with over 500 pharmaceutical companies around the world. As one of the leading enterprises, Huahai Pharmaceutical is the first pharmaceutical company in China that receives FDA approvals for generic drugs.
5001 to 10000 staff
Ambiopharm - A Global Peptide Cdmo
AmbioPharm, a global peptide CDMO, was founded in 2005 and is headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at small to very large scales. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA with excellent outcomes.
501 to 1000 staff
Bristol Myers Squibb
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at:
10001+ staff
Cstone Pharmaceuticals
CStone (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received ten NDA approvals for four drugs. Multiple late-stage drug candidates are now under pivotal clinical trials or registration. CStone's vision is to be a pioneer in enhancing global patient health through innovation.
201 to 500 staff
North China Pharmaceutical Company. Ltd
North China Pharma is a pharmaceuticals company based out of SHIJIAZHUANG, HEB, China.
10001+ staff
Daewoong Pharmaceutical
Daewoong Pharmaceuticals Co, Ltd pursues meaningful work by collaborating with great people, working with autonomy, and choosing opportunities that create shared value for the company, customers, and society. Above all, we are committed to driving real change and innovation through what we do. Establish in 1945, Daewoong Pharmaceuticals is a leading healthcare company in Korea that has achieved consecutive successes in new drug development through constant challenge and innovation. Today, we continue to expand a diverse pipeline and next-generation platform technologies, aiming to develop first-in-class and best-in-class innovative medicines for patients worldwide. Our commitment to global standards is proven by GMP certifications from major regulatory authorities such as the U.S. FDA and EMA, along with ISO certifications that demonstrate our excellence in quality, environmental management, and occupational health and safety systems. At Daewoong, we believe that the growth of our employees fuels the growth of the company. We foster a forward-looking corporate culture by promoting smart work practices, career development, and global talent training programs. Beyond Korea, we strive to become a global healthcare leader by creating new value for healthier lives and better quality of life worldwide.
1001 to 5000 staff
Eli Lilly China
Our history in China can be traced back to early 20thCentury. The company set up its first oversea office in Shanghai in 1918 which was Lilly’s first step into its global presence. After years of baptism, Lilly returned to China in 1993. Over the past 20+ years, adhered to the principle of “In China, For China”, Lilly has been forging ahead in developing the business in China. The Lilly products take leading roles in many therapeutic areas including endocrine, central nervous system and oncology, etc. The company’s innovative medicines like Prozac®, Zyprexa®, Cymbalta®, Straterra®, Gemzar®, Alimta®, Evista ®, Forteo®, Cialis®, Humalog®(insulin lispro)and Tradjenta® are widely used in the medical practices in China. While saving lives and improving patients’ life quality, the Lilly products also provide the healthcare professionals and the medical system with more valuable solutions to reduce the medical cost. The core value of Integrity, Excellence and Respect for People guide Lilly in all that we do, it is same in China as in the entire globe. In China, Lilly is determined to fulfill the integrity of corporate citizenship with the philosophy of In China, For China to provide the newest innovative medicines of highest quality to the patients and their families, saving lives and improving the quality of living. By initiating and implementing the diverse public educational programs, Lilly spare no effort to deliver the disease information and promote health knowledge for the sake of improving people’s life quality. In recognition of Lilly’s contributions as a corporate citizen, the company was granted a number of awards including the “Guangming CSR Award”, “Global Top 500 Companies Charity Award”, “National Special CSR Award of China Association of Enterprises”, “Special Contribution Award” by Ministry of Health, “2015 Best Employer in China”, and “Top Employers China 2017”, etc.
1001 to 5000 staff
Hunan Erkang Pharmaceutical Co., Ltd
Hunan Er-Kang Pharmaceutical Co, Ltd,founded in October 2003,is specialized in the R&D, production, and sale of pharmaceutical products, boasting China’largest-scale pharmaceutical excipient manufacturer with full range of product line and also one of the few enterprises who has obtained Drug Approval Number for sulbenicillin sodium, a new type penicillin. Er-Kang’s products are far sold to over pharmaceutical enterprises worldwide. Er-Kang owns China's best-known state-level R&D Center of Pharmaceutical Excipient and the world’s largest Starch Capsule Industrial Park at annual capacity of 120 billion starch capsules-a new type vegetable capsule superior to an other type of vegetable capsules in the world. In 2014, Hunan Er-kang invested 700 million RMB to build the world’s largest starch vacant capsule Industry Park which is expected to hit the annual capacity of 100 billion vacant capsules once in full operation. As an innovative high-end pharmaceutical excipient, Er-Kang’s starch will trigger a revolution in the capsule industry."Drug Safety Is Above Everything” is the company policy and practice we have been consistently committed to. In the future, we guarantee to take a positive attitude to continuously promote a green ecological circle of pharmaceutical excipient industry, leading the pharmaceutical development in china.
10001+ staff
Salubris Pharmaceuticals Ltd
Salubris is a 10-billion-USD, global integrated pharmaceutical group dedicated to the research, development, manufacture, marketing, distribution, and service of professional pharmaceutical and healthcare products to bring healthier and happier life to people worldwide through world-leading quality and innovations. Shenzhen Salubris Pharmaceuticals Co, Ltd. is a professional pharmaceutical enterprise rooted in China and devoted to improving health worldwide. The company focuses on the newest generation of innovative and specialty medicine, and is an international organization possessing and continuously developing state-of-the-art technologies and products, and has been recognized as an advanced technology enterprise and innovative high-tech company. The company has a team of high-caliber management, R&D, and marketing professionals. It has nationally approved modern GMP pharmaceutical manufacturing facilities, advanced equipment s and testing instruments, producing tablet, capsule, and injection formulations and active pharmaceutical ingredients, with subsidiary branches and marketing network throughout the country.
1001 to 5000 staff
Birdotech
BirdoTech is a state-of-the-art CRO/CDMO. We are committed to providing the highest quality services to drug discovery companies addressing worldwide healthcare needs. The world’s top pharmaceuticals companies and institutes are also our partners. We have been tested to meet time sensitive deadlines supporting critical clinical trials. We leverage our significant scientific foundation to maximize the collaborative value with our partners. With m² of R&D laboratory space distributed over 4 sites throughout China, our partners gain the maximum flexibility in leveraging our services in medicinal chemistry SAR development, synthetic route scouting, process optimization, and production to multi-ton scale.Our success comes from our pursuit of ever more stringent scientific demands. Every challenge is an opportunity to show our commitment to our partner’s success.
501 to 1000 staff
Wuxi Biologics
Our Vision: “Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S, China, Ireland, Germany, and Singapore exceeding liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.
10001+ staff
Gensci
Changchun GeneScience Pharmaceutical Co, Ltd.(GenSci), established in 1997, is a subsidiary of Changchun High-Tech Industries (Group) Co, Ltd.(stock code As a pioneering genetic engineering pharmaceutical company, GenSci stands as Asia's largest manufacturing base for recombinant human growth hormone and the world's exclusive provider of a comprehensive range of recombinant growth hormone products. Driven by the vision of becoming a global leader in pediatric and women's health, GenSci focuses on improving the health and well-being of children and women by offering innovative solutions to address unmet medical needs. The company has expanded its product portfolio beyond its core strengths to include adult endocrinology, dermatology, rheumatology & immunology and oncology with a commitment to addressing more healthcare challenges in diverse therapeutic areas. With nearly 30 years of unwavering dedication to the healthcare industry, GenSci has seamlessly integrated services, marketing, production, and R&D to serve patients worldwide.
5001 to 10000 staff
Hengrui Pharma Co.,ltd
Jiangsu Hengrui Pharmaceuticals Co, Ltd. is a global pharmaceutical company engaged in the development and commercialization of innovative and high-quality drugs, focusing on the research and development of new drugs in the fields of anti-tumor, surgical drugs, autoimmune diseases, metabolic diseases and cardiovascular diseases. Innovation is the core development strategy. Hengrui has 12 innovative products and 1 cooperative innovative product marketed, more than 60 innovative candidates in the R&D stage, and more than 260 trials under clinical development around the world. Hengrui ranked 24th among the top global pharma companies announced by the Torreya in 2021. We have been on the Pharma Exec’s annual listing of the top global pharmaceutical companies for the fourth consecutive year, rising from 47th in 2019 to 32nd in 2022.
10001+ staff
